Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection.
Por:
Boix V, Fedorak RN, Mullane KM, Pesant Y, Stoutenburgh U, Jin M, Adedoyin A, Chesnel L, Guris D, Larson KB and Murata Y
Publicada:
19 ene 2017
Resumen:
Although the incidence of Clostridium difficile infection (CDI) is increasing, available CDI treatment options are limited in terms of sustained response after treatment. This phase 3 trial assessed the efficacy and safety of surotomycin, a novel bactericidal cyclic lipopeptide, versus oral vancomycin in subjects with CDI.
Filiaciones:
Boix V:
Unit of Infectious Diseases, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria de Alicante (ISABIAL) - Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Spain
Fedorak RN:
Division of Gastroenterology, University of Alberta, Edmonton, Canada
Mullane KM:
Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago, Illinois
Pesant Y:
St-Jerome Medical Research Inc., Saint-Jérôme, Quebec, Canada
Stoutenburgh U:
Merck & Co., Inc., Kenilworth, New Jersey
Jin M:
Merck & Co., Inc., Kenilworth, New Jersey
Adedoyin A:
Merck & Co., Inc., Kenilworth, New Jersey
Chesnel L:
Merck & Co., Inc., Kenilworth, New Jersey
Guris D:
Merck & Co., Inc., Kenilworth, New Jersey
Larson KB:
Merck & Co., Inc., Kenilworth, New Jersey
Murata Y:
Merck & Co., Inc., Kenilworth, New Jersey
|